Literature DB >> 9188602

Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression.

R P DeMatteo1, G Chu, M Ahn, E Chang, C F Barker, J F Markmann.   

Abstract

The major barrier to the clinical application of adenovirus gene therapy for diseases that require stable transgene expression is the immunogenicity of recombinant adenovirus, which ordinarily limits the duration of its effects to a period of about 2 weeks. We postulated that tolerance to adenovirus could be induced and transgene expression could be prolonged if T lymphocytes underwent thymic selection in the presence of adenovirus antigens. Mice were inoculated in the thymus with a recombinant adenovirus containing the lacZ marker gene during the neonatal period at a time before T-cell maturation had occurred. When the virus was administered intravenously to these mice in adulthood, they were found to have an impaired adenovirus-specific cytotoxic T-lymphocyte response which allowed prolonged hepatic lacZ expression, for up to 260 days. The ability to achieve unresponsiveness to a recombinant adenovirus after inoculation of the thymus in neonates extends the paradigm of intrathymic tolerance induction. Furthermore, this model will enable the study of stable adenovirus transgene expression in vivo without the use of immunosuppression and ultimately may have clinical utility.

Entities:  

Mesh:

Year:  1997        PMID: 9188602      PMCID: PMC191770          DOI: 10.1128/JVI.71.7.5330-5335.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Induction of donor-specific unresponsiveness by intrathymic islet transplantation.

Authors:  A M Posselt; C F Barker; J E Tomaszewski; J F Markmann; M A Choti; A Naji
Journal:  Science       Date:  1990-09-14       Impact factor: 47.728

2.  Prevention of autoimmune diabetes in the BB rat by intrathymic islet transplantation at birth.

Authors:  A M Posselt; C F Barker; A L Friedman; A Naji
Journal:  Science       Date:  1992-05-29       Impact factor: 47.728

3.  Immunological tolerance to lymphocytic choriomeningitis virus in neonatally infected virus carrier mice: evidence supporting a clonal inactivation mechanism.

Authors:  J Cihak; F Lehmann-Grube
Journal:  Immunology       Date:  1978-02       Impact factor: 7.397

4.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

Review 5.  Gene therapy: adenovirus vectors.

Authors:  K F Kozarsky; J M Wilson
Journal:  Curr Opin Genet Dev       Date:  1993-06       Impact factor: 5.578

Review 6.  Fetal surgical therapy.

Authors:  N S Adzick; M R Harrison
Journal:  Lancet       Date:  1994-04-09       Impact factor: 79.321

7.  Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector.

Authors:  L D Stratford-Perricaudet; M Levrero; J F Chasse; M Perricaudet; P Briand
Journal:  Hum Gene Ther       Date:  1990       Impact factor: 5.695

8.  Viral infection of the thymus.

Authors:  C C King; B D Jamieson; K Reddy; N Bali; R J Concepcion; R Ahmed
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

9.  Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats.

Authors:  Y Ilan; P Attavar; M Takahashi; A Davidson; M S Horwitz; J Guida; N R Chowdhury; J R Chowdhury
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

Review 10.  The basic science of gene therapy.

Authors:  R C Mulligan
Journal:  Science       Date:  1993-05-14       Impact factor: 47.728

View more
  7 in total

Review 1.  Immunological hurdles to lung gene therapy.

Authors:  S Ferrari; U Griesenbach; D M Geddes; E Alton
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

2.  Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.

Authors:  Linlin Gu; Anitra L Farrow; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  J Vis Exp       Date:  2015-05-06       Impact factor: 1.355

3.  Intrathymic adeno-associated virus gene transfer rapidly restores thymic function and long-term persistence of gene-corrected T cells.

Authors:  Marie Pouzolles; Alice Machado; Mickaël Guilbaud; Magali Irla; Sarah Gailhac; Pierre Barennes; Daniela Cesana; Andrea Calabria; Fabrizio Benedicenti; Arnauld Sergé; Indu Raman; Quan-Zhen Li; Eugenio Montini; David Klatzmann; Oumeya Adjali; Naomi Taylor; Valérie S Zimmermann
Journal:  J Allergy Clin Immunol       Date:  2019-09-09       Impact factor: 10.793

4.  Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery.

Authors:  Qiuming Chu; Rodney J Moreland; Lan Gao; Kristin M Taylor; Elizabeth Meyers; Seng H Cheng; Ronald K Scheule
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

5.  Efficient intrathymic gene transfer following in situ administration of a rAAV serotype 8 vector in mice and nonhuman primates.

Authors:  Aurélie Moreau; Rita Vicente; Laurence Dubreil; Oumeya Adjali; Guillaume Podevin; Chantal Jacquet; Jack Yves Deschamps; David Klatzmann; Yan Cherel; Naomi Taylor; Philippe Moullier; Valérie S Zimmermann
Journal:  Mol Ther       Date:  2008-12-16       Impact factor: 11.454

6.  Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha.

Authors:  K Benihoud; I Saggio; P Opolon; B Salone; F Amiot; E Connault; C Chianale; F Dautry; P Yeh; M Perricaudet
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

7.  In situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectors.

Authors:  Gilles Marodon; David Klatzmann
Journal:  BMC Immunol       Date:  2004-08-19       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.